Tazomeline
他唑美林
Report date: 2022/01/14 13:23:58
NME
Base Information
Drug NameTazomeline
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/SEli Lilly And Company
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyNovo Nordisk A/S
Active IndicationsN/A
Inactive Indications